Chr. Hansen Holding A/S has entered into an agreement with Thomas Schäfer to take up the position of Executive Vice President and Chief Scientific Officer.
Thomas is currently employed as Vice President at Novozymes and will take up his new position as soon as possible, expected during the spring of 2017.He will report to the CEO and become a member of the Executive Board.
A German national, Thomas completed his Ph.D. in Microbiology, Physiology & Biochemistry and worked as Assistant Professor at Freie Universität Berlin. He started his career in Novozymes as a PostDoc in 1994 and has held various senior leadership positions in the R&D space in Novozymes since. Since 2013 Thomas has been based in the US.
Thomas has more than 20 years of experience in Industrial Microbiology, R&D, Innovation, Business Development and Mergers & Acquisitions, covering both bacteria and enzymes, and he has published several papers, and he is also the co-inventor on a number of patents.
Thomas will lead Chr. Hansen’s scientific organization for Food Cultures and Enzymes, and for Health and Nutrition (the R&D organization for the Microbial Solutions Platform). This organization consists of 210 employees, largely based at company headquarters in Denmark. Currently the core activities are organized in 5 departments: Discovery, Development, Process, Analytics and Resource & Planning.
Including Thomas Schäfer into the Executive Board is a signal of the importance Chr. Hansen places on its innovation and science as an area critical in securing continuous growth. Thomas brings extensive experience from various disciplines and segments in the scientific space.
“In hiring Thomas, Chr. Hansen brings onboard a very skilled and business-oriented technology leader with international experience. The overall goal of the R&D Microbial Platform is to secure a common and strong scientific backbone within industrial microbes that can sustain new innovations for the Food Cultures & Enzymes and Health & Nutrition Business Units and support Chr. Hansen’s undisputed leadership in bacterial fermentation technology. I am happy to welcome Thomas to the Executive Board”, says CEO Cees de Jong.
“I really look forward to joining Chr. Hansen. I have followed the fantastic growth of this company for many years, so it is great to become a part of the journey”, says Thomas Schäfer.
Once Thomas has joined, the Executive Board will consist of: CEO Cees de Jong, CFO Søren Westh Lonning, COO Knud Vindfeldt, and CSO Thomas Schäfer.
For media inquiries:
Camilla Lercke, Head of Media Relations DKCALE@chr-hansen.com, Tel: +45 53 39 23 84
For investor relations:
Anders Mohr Christensen, Vice President, Investor Relations DKAMC@chr-hansen.com, Tel: +45 45 74 76 18
科汉森是为食品、营养、制药和农业行业开发天然解决方案的一家全球领先的生物科学公司。我们为各种食品、糖果、饮料、膳食补充剂、动物饲料和植物保护开发和生产发酵剂、酶、益生菌和天然色素。我们的产品创新基于大约 40,000 株微生物菌株——我们喜欢称之为“有益菌群”。我们的解决方案帮助食品制造商实现以更少的资源生产更多的产品，同时也减少了化学添加剂和其他合成物添加剂的使用，这使得我们的产品与当今世界息息相关。可持续性是科汉森改善食物和健康的愿景不可分割的一部分。2019 年，科汉森被 Corporate Knights 评为全球最可持续发展的公司，这要归功于我们为可持续发展付出的巨大努力以及我们与客户建立的众多合作伙伴关系。145 年来，我们一直在不断地为我们的合作伙伴以及全球终端消费者创造价值。令我们感到自豪的是，每天有超过 10 亿人在消费含有我们天然成分的产品。科汉森成立于 1874 年，并已在哥本哈根证券交易所上市。